API
< Back to all clusters
[BUSINESS] · United Kingdom, France · 2 sources

started · updated

Mironid raises $46 million for rare kidney disease therapeutics

Glasgow-based biopharmaceutical company Mironid has raised $46 million (£34 million) in Series B funding to advance its development of treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

ADPKD is a life-threatening hereditary kidney disorder affecting more than 12 million people globally. Mironid is developing a first-in-class class of small molecules known as LoAc, which directly target cyclic AMP (cAMP). Preclinical data indicates these molecules can reduce cyst number and kidney volume with a favorable safety profile.

The funding round included new investor the Scottish National Investment Bank, alongside existing investors such as Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. The capital will be used to progress the clinical development of the company’s lead candidate.

Entities

Mironid · Neil Wilkie · Roche Venture Fund · Scottish National Investment Bank